GALT
Income statement / Annual
Last year (2023), Galectin Therapeutics Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Galectin Therapeutics Inc.'s net income was -$41.07 M.
See Galectin Therapeutics Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$33,000.00 |
$32,000.00 |
$41,000.00 |
$36,000.00 |
$35,000.00 |
$0.00 |
$1,000.00 |
$7,000.00 |
$7,000.00 |
$0.00 |
| Gross Profit |
-$33,000.00 |
-$32,000.00 |
-$41,000.00 |
-$36,000.00 |
-$35,000.00 |
$0.00 |
-$1,000.00 |
-$7,000.00 |
-$7,000.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$32.13 M
|
$31.74 M
|
$23.82 M
|
$17.98 M
|
$7.47 M
|
$6.47 M
|
$11.72 M
|
$15.33 M
|
$13.11 M
|
$8.43 M
|
| General & Administrative
Expenses |
$5.94 M
|
$6.62 M
|
$6.36 M
|
$5.47 M
|
$5.97 M
|
$7.13 M
|
$4.53 M
|
$6.16 M
|
$6.97 M
|
$7.01 M
|
| Selling & Marketing
Expenses |
$44,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$5.94 M
|
$6.62 M
|
$6.36 M
|
$5.47 M
|
$5.97 M
|
$7.13 M
|
$4.53 M
|
$6.16 M
|
$6.97 M
|
$7.01 M
|
| Other Expenses |
-$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$38.07 M |
$38.35 M |
$30.18 M |
$23.44 M |
$13.44 M |
$13.60 M |
$16.25 M |
$21.48 M |
$20.08 M |
$15.43 M |
| Cost And Expenses |
$38.07 M |
$38.35 M |
$30.18 M |
$23.44 M |
$13.44 M |
$13.60 M |
$16.25 M |
$21.48 M |
$20.08 M |
$15.43 M |
| Interest Income |
$230,000.00 |
$52,000.00 |
$3,000.00 |
$66,000.00 |
$231,000.00 |
$38,000.00 |
$24,000.00 |
$45,000.00 |
$52,000.00 |
-$358,000.00 |
| Interest Expense |
-$2.79 M |
$1.03 M |
$489,000.00 |
$87,000.00 |
$87,000.00 |
$336,000.00 |
$12,000.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$38.07 M
|
$32,000.00
|
$41,000.00
|
$36,000.00
|
$35,000.00
|
$1,000.00
|
$1,000.00
|
$7,000.00
|
$7,000.00
|
$10,000.00
|
| EBITDA |
-$202,000.00
|
-$37.71 M
|
-$30.00 M
|
-$23.34 M
|
-$13.17 M
|
-$13.56 M
|
-$16.23 M
|
-$21.47 M
|
-$20.07 M
|
-$15.78 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$2.99 M
|
-$424,000.00
|
-$348,000.00
|
-$21,000.00
|
$144,000.00
|
-$298,000.00
|
$12,000.00
|
$45,000.00
|
$52,000.00
|
-$358,000.00
|
| Income Before Tax |
-$41.07 M |
-$38.78 M |
-$30.53 M |
-$23.47 M |
-$13.29 M |
-$13.90 M |
-$16.24 M |
-$21.44 M |
-$20.03 M |
-$15.79 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
$424,000.00 |
$448,000.00 |
$51,000.00 |
$87,000.00 |
-$123,141.00 |
$24,000.00 |
$0.00 |
$0.00 |
-$52,000.00 |
| Net Income |
-$41.07 M |
-$39.20 M |
-$30.98 M |
-$23.52 M |
-$13.38 M |
-$13.90 M |
-$16.24 M |
-$21.44 M |
-$20.03 M |
-$15.79 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-0.74 |
-0.66 |
-0.53 |
-0.41 |
-0.26 |
-0.35 |
-0.46 |
-0.73 |
-0.83 |
-0.72 |
| EPS Diluted |
-0.74 |
-0.66 |
-0.53 |
-0.41 |
-0.26 |
-0.35 |
-0.46 |
-0.73 |
-0.83 |
-0.72 |
| Weighted Average Shares
Out |
$60.16 M
|
$59.39 M
|
$58.53 M
|
$57.03 M
|
$52.24 M
|
$39.41 M
|
$35.52 M
|
$29.22 M
|
$24.12 M
|
$21.85 M
|
| Weighted Average Shares
Out Diluted |
$60.16 M
|
$59.39 M
|
$58.53 M
|
$57.03 M
|
$52.24 M
|
$39.41 M
|
$35.52 M
|
$29.22 M
|
$24.12 M
|
$21.85 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
